Deciphering the DNA Methylome of Polycystic Ovary Syndrome

Tan, Qihua

Article type: Current Opinion

Deciphering the DNA methylome of polycystic ovary syndrome

Running heading: Epigenomics of PCOS

Qihua Tan[1,2,*]

1. Epidemiology and Biostatistics, Department of Public Health, University of Southern

   Denmark, Odense, Denmark

2. Unit of Human Genetics, Department of Clinical Research, University of Southern
   Denmark, Odense, Denmark

*Addresses for correspondence:

Qihua Tan, MD, PhD

Unit of Human Genetics, Department of Clinical Research

University of Southern Denmark

J. B. Winsløws Vej 9B

DK-5000, Odense C

Denmark

Tel. 0045 65504236

e-mail:qtan@health.sdu.dk

Abstract

Polycystic ovary syndrome (PCOS) is a hormonal disorder common among women of reproductive age. PCOS is characterized by ovarian dysfunction and metabolic abnormalities with widely varying clinical manifestations brought about by intricate mechanisms of interplay between the genome and the environment. The popularity of epigenome-wide association studies (EWAS) is helping to facilitate the discovery of environment-mediated molecular modification in PCOS from disease etiology to epigenetic marker discovery. Current epigenetic studies have provided convincing observational evidence linking epigenetic regulation with PCOS origin, manifestation, clinical heterogeneity and comorbidity which could lead to improved management of the disease through efficient intervention and prevention strategies. Several biological pathways have been consistently reported by independent studies revealing functional regulation due to endocrine abnormalities and metabolic dysfunction in PCOS, while also suggesting an autoimmune component in the condition. The use of high-throughput sequencing technologies for analysing the epigenome integrated with causal inferences are expected to facilitate effective and efficient PCOS management to promote reproductive health.

Key points

1. Epigenetic studies help to elucidate the intricate interplay between the genome and the environment in PCOS development and manifestation.

2. New approaches in omics techniques and experiment design will enable identification of causal epigenetic biomarkers to serve as targets for efficient intervention and prevention of PCOS

1. Background

Polycystic ovary syndrome (PCOS) is a complex condition representing a group of symptoms that result from hormonal and metabolic abnormalities, and is the most common endocrine dysfunction in reproductive age women and is often associated with infertility. According to the widely accepted Rotterdam diagnostic criteria, any woman presenting with at least two of the three following characteristics: clinical and/or biochemical hyperandrogenism, menstrual irregularities (oligo- and/or anovulation) due to ovulatory dysfunction, polycystic ovarian morphology, and exclusion of other aetiologies (congenital adrenal hyperplasias, androgen-secreting tumours, Cushing's syndrome), can be diagnosed as PCOS [1]. The assessment of PCOS is usually straightforward including clinical (hirsutism, oligomenorrhoea or amenorrhoea and evaluation of ovarian morphology by ultrasonography), endocrine (high serum concentrations of free testosterone, or high circulating concentrations of anti-Mullërian hormone, increased luteinizing hormone (LH)/ follicle stimulating hormone (FSH) ratio) and metabolic (insulin resistance, metabolic cardiovascular syndrome, dyslipidaemia, high rates of premature impaired glucose tolerance, type 2 diabetes and increased cardiovascular risk factors) features. The treatment strategies are mostly symptom-oriented with therapeutic approaches targeting hyperandrogenism and/or the associated metabolic disorders [2]. PCOS is likely a result of interactions between genetic susceptibility and environmental exposures including, toxins, diet and nutrition, inactivity, socioeconomic status, and geography [3], leading to heterogeneous expression of the syndrome. A twin-family study has estimated an heritability of around 60% [4]. A recent large-scale genome-wide meta-analysis reported a dozen loci associated with the risk of PCOS [5] indicating shared genetic architecture across the heterogeneous expression of the condition. Moreover, animal studies have shown PCOS-like phenotypes including ovarian

dysfunction induced by prenatal exposure to excessive androgen [6], suggesting the important roles of environmental interference in PCOS development through fetal programming.

By definition, epigenetics as the study of readily reversible mitotically and/or meiotically heritable changes that do not entail a change in DNA sequence [7]. Epigenetic modifications can be grouped into three main mechanisms: DNA methylation, histone modifications and RNA-based mechanisms. Among them, DNA methylation is one of the best understood, most readily measureable and widely analysed molecular modifications in current epigenome-wide association studies (EWAS). The widespread use of high throughput technologies such as the microarray-based genome-wide DNA methylation analysis (e.g. Illumina BeadChip Arrays) and the whole-genome bisulfite sequencing (WGBS) powered by next-generation sequencing (NGS) [8] is revolutionizing our exploration and understanding of the molecular basis of PCOS development and clinical manifestations brought about by intricate interplay between our genome and environmental exposure. This paper focuses on recent development in DNA methylome association studies on PCOS by summarizing the major findings and giving author opinions on the biological and clinical implications as well as pointing out limitations for further improvement.

2. Epigenetics in PCOS pathogenesis

The pathogenesis of PCOS is still not precisely known [9, 10] with different hypotheses [11-13] concerning hormonal imbalance, insulin resistance, genetic inheritance and inflammation. Among the different hypothesis, the most widely accepted is the developmental origin of PCOS [12,13]. There has been firm evidence from experimental studies of animal model showing that exposure to excess androgen during fetal life of rhesus monkeys [14,15], sheep [16-18] and rats

4

[19,20] could lead to pathophysiological changes closely resembling the clinical features in

PCOS women. It is ethically challenging to replicate these experiments in humans. However,

supportive clinical data have been reported by studies on female fetuses with molecular

deficiencies that led to prenatal hyperandrogenemia [21,22]. Interestingly, these females

manifested PCOS features later in life.

It has been shown young maternal age and excessive maternal weight gain may increase

the prenatal androgen exposure of female fetuses [23]. Barrett et al. [24] reported that prenatal

exposure to stressful life events may masculinize some aspects of female reproductive

development in humans. A recent methylation profiling of granulosa cells found that altered

methylation in *AKR1C3, GHRHR, MAMLD1, RETN* and *TNF* genes indirectly contribute to

androgen excess in PCOS patients [25]. Li and Huang [26] proposed the 'epigenetic abnormality'

hypothesis for PCOS development, which considers that in utero exposure of the developing

female fetus to high maternal androgens may disturb the epigenetic reprogramming of its

reproductive tissue and result in development of PCOS-like phenotypes in adulthood. The

hypothesis further postulated that the incomplete erasure of the epigenetic abnormality in germ

cells after fertilization would confer intergenerational inheritance of PCOS. The epigenetic

mechanism underlying the development of PCOS-like phenotypes in prenatally androgenized

animals and the intergenerational inheritance of these phenotypes have also been revealed using

the microarray technology [15,20]. Multiple biological pathways were found to be significantly

regulated including antiproliferative role of TOB in T cell signalling and transforming growth

factor-β signalling [15]. Their results suggest that prenatal androgenisation may predispose to

PCOS via alteration of the epigenome. Even those who argue against the fetal origin hypothesis

have speculated that the epigenetic mechanism is involved in the "developmental window" of PCOS spanning well beyond the fetal life [27].

3. EWAS and PCOS comorbidity

Epidemiological studies have shown that PCOS patients are at a higher risk for metabolic and psychiatric comorbidities [28] with prevalence of metabolic diseases differs from geographic region and ethnicity. For example, while De Leo [29] found about 60-70% of Italian PCOS patients are obese, a Chinese study [30] reported a prevalence of 18.2% for metabolic syndrome in Chinese PCOS patients. Nevertheless, metabolic disorder is the most common comorbidity with PCOS. It is interesting that, although pathways related to metabolic and psychiatric diseases were also enriched by significant methylation sites, the most frequently reported functional pathways in EWASs are, however, implicated in autoimmune diseases (e.g. type I diabetes mellitus, thyroid disease and asthma pathways), as suggested by EWAS on PCOS in ovarian tissue [31], in whole blood [32,33] and in skeletal muscle [34], suggesting a common mechanism across tissues. Note that the study by Shen et al. [33] was conducted using a genome-wide methylated DNA immunoprecipitation (MeDIP) analysis with a higher coverage of the DNA methylome than the microarray-based analysis used by the other studies. By comparing the nationwide Danish population of PCOS patients with a large control group, Glintborg et al. [35] reported significantly increased prevalence for multiple diseases in PCOS patients including autoimmune diseases. In their analysis, about 10% of PCOS patients were also diagnosed with autoimmune diseases. In the literature, high prevalence of autoimmune disorders was also observed in PCOS patients [36-38]. Although the prevalence of autoimmune diseases is not as high as metabolic disorders in PCOS patients, it is present across populations with notably high frequencies. Here, it is interesting that the epidemiological observations are supported by

biological pathways that were significantly over-represented by the differentially methylated genomic sites identified by EWAS on different tissues of PCOS patients, and using different platforms for DNA methylation analysis. In a published EWAS on PCOS [32], we also found systemic lupus erythematosus pathway as differentially regulated under PCOS condition, providing further support to an autoimmune involvement in PCOS. To sum up, results from current epigenetic studies on PCOS provide revealing observational evidences that link PCOS with autoimmune diseases [39,40].

4. Epigenetics in PCOS clinical and biochemical heterogeneity

As a complex disorder, PCOS is heterogeneous clinically and biochemically, with the commonly associated features neither uniform nor universal [41,42]. The molecular basis underlying the heterogeneous clinical expression of PCOS has been investigated using high-throughput omics approaches and reported molecular biomarkers for metabolic heterogeneity [33,43]. Based on genomic DNA methylation profiles measured in our PCOS patients, we conducted epigenetic association analyses on multiple clinical and biochemical features including metabolic parameters [32]. Highly significant epigenetic associations were observed in PCOS patients for multiple reproductive hormones including estradiol, prolactin and progesterone. Although we observed comparable mean levels of the three hormones in PCOS patients and healthy controls (p>0.38), the levels of estradiol and prolactin displayed larger dispersions (2.5 to 97.5 quantiles) in PCOS samples (13.8-151.5 pg/ml for estradiol; 4-55 ng/ml for prolactin) as compared with the controls (27.9-115.9 pg/ml for estradiol; 5.8-27.2 ng/ml prolactin) [32]. The data suggests higher heterogeneity in the patient groups which could be regulated by DNA methylation at the identified significant CpG sites. Interestingly, the significant CpGs were identified in association analysis of the hormones in PCOS samples only. Similar epigenetic association analysis on the

7

levels of estradiol and prolactin performed on the healthy controls failed to detect any significant CpG indicating that the significant results were driven by the large variation or heterogeneity in the levels of these hormones in PCOS patients. The CpG sites significantly associated with prolactin levels in the patient group were linked to immune reaction and autoimmune diseases (diabetes and thyroid disease) while CpGs associated with estradiol were involved in biological pathways for synthesis of reproductive hormone and for drug metabolism. Very recently, we have performed a genomic region based association analysis of epigenetic regulation on PCOS heterogeneity and identified seven differentially methylated regions (DMR) on chromosome 19 (12877188-12876846 bp) and chromosome 6 (MHC region) associated with prolactin level, as well as chromosomes 11 and 2 associated with metabolic attributes [44]. Functional annotation linked the significant DMRs to functional genes (*HOOK2, BDNF, HLA-G, HLA-H, HLA-J, RNF39*, etc) of metabolic disorders and immunity. Interestingly, Jones et al. [45] found genetic variations at *LHCGR* and *INSR* regions differentially methylated/expressed in PCOS patients stratified by obesity, suggesting involvement of cis-methylation quantitative trait loci (meQTL) and cis-expression quantitative loci (eQTL) in regulating PCOS sub-phenotypes. These novel results emphasize the important roles of both genetic and epigenetic regulations behind the observed heterogeneity in the clinical and biochemical expressions of PCOS.

5. Challenges in epigenetic biomarker discovery

Although the literature of epigenetic studies on PCOS has grown considerably, identifying epigenetic biomarkers for PCOS is still challenging due to multiple factors including limitation of experiment design [46], patient heterogeneity, ethnic differences in the expression of PCOS [47], as well as limited availability of tissue biopsies such as skeletal muscle and ovarian tissue for investigating tissue-specific methylation patterns. It is true that consistent functional

pathways have been found in studies using different tissues, but no replication of the significant

CpG sites across studies have been reported except for some overlapping results at gene level,

e.g. the *OXPHOS* genes in the EWAS by Nilsson et al. [34] and the gene expression analysis by

Skov et al. [48], both using skeletal muscle. Instead of focusing on single CpGs, a better strategy

would be to perform replications at the gene level to define epigenetic biomarkers for PCOS.

Moreover, considering the heterogeneous expression of PCOS, it is biologically more sensible to

look for epigenetic markers for PCOS clinical sub-phenotypes in well categorized/stratified

patients, because a specific sub-phenotype is supposed to be under closer epigenetic modification

than the composite phenotype of PCOS.

It is necessary to point out that nearly all EWASs on PCOS are observational studies by

nature. In epidemiology, observational studies are considered to have less probative force due to

inherent limitation in controlling confounding factors that influence both explanatory (exposure,

here DNA methylation) and clinical or health outcome (here PCOS) variables, a situation that

can result in biased, confusing and even misleading results [49]. As a matter of fact, a significant

epigenetic association does not guarantee a causal effect, but just a superficial correlation or

coincidence. This means that the identified significant markers from EWAS on PCOS could be

meaningless for intervention purpose if they are not causal [47]. In fact, efforts have been made

to infer causality from observational studies [50] with effective and valuable approaches

proposed such as propensity score matching [51]. Through examining the cross-trait cross-pair

correlation between the predictor of one relative and the outcome of the other relative, Hopper

and colleagues performed "inference on causation studies from the examination of familial

confounding factors" (ICE FALCON) using regression analysis [52]. The method has been

recently applied to EWASs using twins, and reported causal effects of smoking [53] and body

mass index [54] on site-specific DNA methylation variations in blood cells. Introducing causal inference in EWASs on PCOS using different tissues should help to verify and identify causal epigenetic biomarkers (tissue specific and non-specific) to serve as targets for efficient prevention, intervention and management.

6. Conclusions

Epigenetic association studies are gaining popularity because they offer an appealing tool for studying PCOS, a complex and heterogeneous condition mediated by individual genetic makeups (nature) and disrupting prenatal and/or postnatal environments (nurture). Current EWASs on PCOS have revealed convincing observational evidence in relating epigenetic modification with PCOS development and manifestation which could contribute to efficient management of the disease and promote reproductive health. The epigenetic study on PCOS will further benefit from the NGS-based whole genome DNA methylation analysis and from emerging approaches for genome-wide profiling of histone modifications and for analysing post-transcriptional regulations. Introducing causal inference in epigenetic association studies is going to enable identification of causal epigenetic biomarkers, functional genes and biological pathways for revealing the underlying aetiology of PCOS and enabling efficient and effective management of the disorder.

Compliance with Ethical Standards

References

1. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 2004; 19:41–47.

2. Escobar-Morreale H. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol 2018; 14:270–284.

3. Merkin SS, Phy JL, Sites CK, Yang D. Environmental determinants of polycystic ovary syndrome. Fertil Steril. 2016;106(1):16-24.

4. Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab. 2006; 91:2100-2104.

5. Day F, Karaderi T, Jones MR, Meun C, He C, Drong A, et al. Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genet 2018; 14(12): e1007813.

6. Rodriguez Paris V, Bertoldo MJ. The Mechanism of Androgen Actions in PCOS Etiology. Med Sci (Basel). 2019;7(9):89.

7. Schuebel K, Gitik M, Domschke K, Goldman D. Making Sense of Epigenetics. Int J Neuropsychopharmacol. 2016;19(11):pyw058. doi:10.1093/ijnp/pyw058

8. Li Y, Tollefsbol TO. DNA methylation detection: bisulfite genomic sequencing analysis. Methods Mol. Biol. 2011; 791:11-21.

9. Motta AB. Epigenetic marks in Polycystic Ovary Syndrome. Curr Med Chem. 2019; doi: 10.2174/0929867326666191003154548.

10. Vázquez-Martínez ER, Gómez-Viais YI, García-Gómez E, Reyes-Mayoral C, Reyes-Muñoz E, Camacho-Arroyo I, Cerbón M. DNA methylation in the pathogenesis of polycystic ovary syndrome. Reproduction. 2019;158(1):R27-R40.

11. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocrine reviews, 2016; 37(5):467-520 .

12. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome - a hypothesis. J Endocrinol. 2002;174(1):1-5.

13. Gur EB, Karadeniz M, Turan GA. Fetal programming of polycystic ovary syndrome. World J Diabetes. 2015;6(7):936-942.

14. Abbott DH, Tarantal AF, Dumesic DA. Fetal, infant, adolescent and adult phenotypes of polycystic ovary syndrome in prenatally androgenized female rhesus monkeys. Am J Primatol. 2009;71(9):776-784.

15. Xu N, Kwon S, Abbott DH, Geller DH, Dumesic DA, Azziz R, Guo X, Goodarzi MO. Epigenetic mechanism underlying the development of polycystic ovary syndrome (PCOS)-like phenotypes in prenatally androgenized rhesus monkeys. PLoS One. 2011;6(11):e27286.

16. Hogg K, McNeilly AS, Duncan WC. Prenatal androgen exposure leads to alterations in gene and protein expression in the ovine fetal ovary. Endocrinology. 2011;152(5):2048-2059.

17. Connolly F, Rae MT, Späth K, Boswell L, McNeilly AS, Duncan WC. In an Ovine Model of Polycystic Ovary Syndrome (PCOS) Prenatal Androgens Suppress Female Fetal Renal Gluconeogenesis. PLoS One. 2015;10(7):e0132113.

18. Ramaswamy S, Grace C, Mattei A, et al. Developmental programming of polycystic ovary syndrome (PCOS): prenatal androgens establish pancreatic islet α/β cell ratio and subsequent insulin secretion. Sci Rep 2016; 6:27408

19. Wang F, Yu B, Yang W, Liu J, Lu J, Xia X. Polycystic ovary syndrome resembling histopathological alterations in ovaries from prenatal androgenized female rats. J Ovarian Res. 2012;5(1):15.

20. Nilsson E, Larsen G, Manikkam M, Guerrero-Bosagna C, Savenkova MI, Skinner MK. Environmentally induced epigenetic transgenerational inheritance of ovarian disease. PLoS One. 2012;7(5):e36129.

21. Hague WM, Adams J, Rodda C, Brook CG, de Bruyn R, Grant DB, Jacobs HS. The prevalence of polycystic ovaries in patients with congenital adrenal hyperplasia and their close relatives. Clin Endocrinol (Oxf). 1990;33(4):501-510.

22. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 1995;80(12):3689-3698.

23. Kallak TK, Hellgren C, Skalkidou A, Sandelin-Francke L, Ubhayasekhera K, Bergquist J, Axelsson O, Comasco E, Campbell RE, Sundström Poromaa I. Maternal and female

fetal testosterone levels are associated with maternal age and gestational weight gain. Eur J Endocrinol. 2017;177(4):379-388.

24. Barrett ES, Parlett LE, Sathyanarayana S, et al. Prenatal exposure to stressful life events is associated with masculinized anogenital distance (AGD) in female infants. Physiol Behav. 2013;114-115:14–20.

25. Sagvekar P, Kumar P, Mangoli V, Desai S, Mukherjee S. DNA methylome profiling of granulosa cells reveals altered methylation in genes regulating vital ovarian functions in polycystic ovary syndrome. Clin Epigenetics. 2019;11(1):61.

26. Li Z, Huang H. Epigenetic abnormality: a possible mechanism underlying the fetal origin of polycystic ovary syndrome. Med Hypotheses. 2008;70:638–642.

27. Franks S, Berga SL. Does PCOS have developmental origins? Fertil Steril. 2012;97(1):2-6.

28. Gilbert EW, Tay CT, Hiam DS, Teede HJ, Moran LJ. Comorbidities and complications of polycystic ovary syndrome: An overview of systematic reviews. Clin Endocrinol (Oxf). 2018;89(6):683-699.

29. De Leo V, Musacchio MC, Palermo V, Di Sabatino A, Morgante G, Petraglia F. Polycystic ovary syndrome and metabolic comorbidities: therapeutic options. Drugs Today (Barc). 2009;45(10):763-775.

30. Li R, Yu G, Yang D, Li S, Lu S, Wu X, Wei Z, Song X, Wang X, Fu S, Qiao J. Prevalence and predictors of metabolic abnormalities in Chinese women with PCOS: a cross- sectional study. BMC Endocr Disord. 2014;14:76.

31. Wang XX, Wei JZ, Jiao J, Jiang SY, Yu DH, Li D. Genome-wide DNA methylation and gene expression patterns provide insight into polycystic ovary syndrome development. Oncotarget. 2014;5(16):6603-6610.

32. Li S, Zhu D, Duan H, Ren A, Glintborg D, Andersen M, Skov V, Thomassen M, Kruse T, Tan Q. Differential DNA methylation patterns of polycystic ovarian syndrome in whole blood of Chinese women. Oncotarget. 2017;8(13):20656-20666.

33. Shen HR, Qiu LH, Zhang ZQ, Qin YY, Cao C, Di W. Genome-wide methylated DNA immunoprecipitation analysis of patients with polycystic ovary syndrome. PLoS One. 2013;8(5):e64801.

34. Nilsson E, Benrick A, Kokosar M, Krook A, Lindgren E, Källman T, Martis MM, Højlund K, Ling C, Stener-Victorin E. Transcriptional and Epigenetic Changes Influencing Skeletal Muscle Metabolism in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2018;103(12):4465-4477.

35. Glintborg D, Hass Rubin K, Nybo M, Abrahamsen B, Andersen M. Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome. Eur J Endocrinol. 2015;172:627-638.

36. Janssen OE, Mehlmauer N, Hahn S, Offner AH, Gärtner R. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol. 2004;150:363-369.

37. Du D & Li X. The relationship between thyroiditis and polycystic ovary syndrome: a meta-analysis. Int J Clin Exp Med. 2013; 25; 6:880-889.

38. Gaberšček S, Zaletel K, Schwetz V, Pieber T, Obermayer-Pietsch B, Lerchbaum E. Mechanisms in endocrinology: thyroid and polycystic ovary syndrome. Eur J Endocrinol. 2015; 172:R9-21.

39. Arora S, Sinha K, Kolte S, Mandal A. Endocrinal and autoimmune linkage: Evidences from a controlled study of subjects with polycystic ovarian syndrome. J Hum Reprod Sci 2016;9:18-22

40. Mobeen H, Afzal N, Kashif M. Polycystic ovary syndrome may be an autoimmune disorder. Scientifica (Cairo). 2016;2016:4071735.

41. Bouchard P, Fauser BC. PCOS: an heterogeneous condition with multiple faces for multiple doctors. Eur J Endocrinol. 2014;171(4):E1-2.

42. Zhang HY, Guo CX, Zhu FF, Qu PP, Lin WJ, Xiong J. Clinical characteristics, metabolic features, and phenotype of Chinese women with polycystic ovary syndrome: a large-scale case-control study. Arch Gynecol Obstet. 2013;287:525-531.

43. Escobar-Morreale HF, Samino S, Insenser M, Vinaixa M, Luque-Ramírez M, Lasunción MA, Correig X. Metabolic heterogeneity in polycystic ovary syndrome is determined by obesity: plasma metabolomic approach using GC-MS. Clin Chem. 2012;58:999-1009.

44. Jacobsen VM, Li S, Wang A, Zhu D, Liu M, Thomassen M, Kruse T, Tan Q. Epigenetic association analysis of clinical sub-phenotypes in patients with polycystic ovary syndrome (PCOS). Gynecol Endocrinol. 2019;35(8):691-694.

45. Jones MR, Brower MA, Xu N, Cui J, Mengesha E, Chen Y-DI, et al. Systems Genetics Reveals the Functional Context of PCOS Loci and Identifies Genetic and Molecular Mechanisms of Disease Heterogeneity. PLoS Genet 2015; 11(8): e1005455.

46. Tan Q. Harnessing the power of twins in epigenetic association studies: causal inference and more. Epigenomics. 2020;12(1):1-3.

47. Engmann L, Jin S, Sun F, Legro RS, Polotsky AJ, Hansen KR, Coutifaris C, Diamond MP, Eisenberg E, Zhang H, Santoro N. Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype. Am J Obstet Gynecol. 2017;216(5):493.e1–493.e13.

48. Skov V, Glintborg D, Knudsen S, Jensen T, Kruse TA, Tan Q, Brusgaard K, Beck-Nielsen H, Højlund K. Reduced expression of nuclear-encoded genes involved in mitochondrial oxidative metabolism in skeletal muscle of insulin-resistant women with polycystic ovary syndrome. Diabetes. 2007;56(9):2349-2355.

49. Rush CJ, Campbell RT, Jhund PS, Petrie MC, McMurray JJV. Association is not causation: treatment effects cannot be estimated from observational data in heart failure. Eur Heart J. 2018;39(37):3417-3438

50. Listl S, J¨urges H, Watt RG. Causal inference from observational data. Community Dent. Oral Epidemiol. 2016; 44(5):409–415.

51. Nguyen MH, Yang HI, Le A et al. Reduced incidence of hepatocellular carcinoma in cirrhotic and noncirrhotic patients with chronic hepatitis B treated with Tenofovir – a propensity score-matched study. J. Infect. Dis. 2019; 219(1):10–18.

52. Dite GS, Gurrin LC, Byrnes GB, et al. Predictors of mammographic density: insights gained from a novel regression analysis of a twin study. Cancer Epidemiol Biomarkers Prev. 2008;17(12):3474–3481.

53. Li S, Wong EM, Bui M, Nguyen TL, Joo JE, Stone J, Dite GS, Giles GG, Saffery R, Southey MC, Hopper JL. Causal effect of smoking on DNA methylation in peripheral blood: a twin and family study. Clin Epigenetics. 2018;10:18

54. Li S, Wong EM, Bui M, Nguyen TL, Joo JE, Stone J, Dite GS, Dugué PA, Milne RL, Giles GG, Saffery R, Southey MC, Hopper JL. Inference about causation between body mass index and DNA methylation in blood from a twin family study. Int J Obes (Lond). 2019;43(2):243-252